MK-6482-015, NCT04924075 / 2020-005028-13: Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations |
|
|
| Recruiting | 2 | 322 | Europe, Canada, Japan, US, RoW | Belzutifan, MK-6482, WELIREG™ | Merck Sharp & Dohme LLC | Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers | 02/27 | 02/27 | | |
